<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3208">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351152</url>
  </required_header>
  <id_info>
    <org_study_id>HGEN003-06</org_study_id>
    <nct_id>NCT04351152</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19</brief_title>
  <official_title>A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanigen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Humanigen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess whether the use of lenzilumab in addition to&#xD;
      current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS)&#xD;
      and improve ventilator-free survival in hospitalized subjects with severe or critical&#xD;
      COVID-19 pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In COVID-19, high levels of granulocyte macrophage-colony stimulating factor (GM-CSF) and&#xD;
      inflammatory myeloid cells correlate with disease severity, cytokine storm, and respiratory&#xD;
      failure. The mortality rate for hospitalized COVID-19 patients remains unacceptably high,&#xD;
      particularly in patients who progress to invasive mechanical ventilation (IMV). This&#xD;
      randomized, double-blind, multicenter, placebo-controlled pivotal phase 3 trial will evaluate&#xD;
      the impact of lenzilumab (anti-human GM-CSF monoclonal antibody) on ventilator-free survival&#xD;
      in hospitalized, hypoxic patients with COVID-19. The study is also designed to evaluate other&#xD;
      key endpoints, including ventilator-free days, duration of ICU stay, incidence of IMV, ECMO&#xD;
      and/or death, time to death, all-cause mortality and time to recovery.&#xD;
&#xD;
      Approximately 516 patients will be randomized to receive lenzilumab + SOC vs. placebo + SOC&#xD;
      in a 1:1 ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free Survival</measure>
    <time_frame>Up to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free Days</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Intensive Care Unit (ICU) Stay</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Invasive Mechanical Ventilation, ECMO and/or Death</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to recovery is defined as the first day on which a subject satisfies one of the following 3 categories from the 8-point ordinal scale (Hospitalized, not requiring supplemental oxygen-no longer requires ongoing medical care; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no limitations on activities).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe acute respiratory distress syndrome (ARDS)</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in 1 or 2 Categories using 8-point Ordinal Scale</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Alive and Off Oxygen</measure>
    <time_frame>Up to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Adverse Events</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Serious Adverse Events</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Using the NCI CTCAE version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Discharged from Hospital</measure>
    <time_frame>Up to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement in oxygenation for &gt; 48 hours</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Non-invasive Ventilation (or Use of High-flow Oxygen Device)</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Improvement, Defined as NEWS2 &lt; 2 Maintained for 24 Hours</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>NEWS2 consists of: Physiological Parameters: respiration rate (per minute), SpO2 Scale 1 (%), SpO2 Scale 2 (%), use of air or oxygen, systolic blood pressure (mmHg), pulse (per minute), consciousness and temperature (°C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 28 in Clinical status Based on the 8-point Ordinal Scale</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Time on Low-flow or High-flow Supplemental Oxygen</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">516</enrollment>
  <condition>Coronavirus Disease 2019 (COVID-19) Pneumonia</condition>
  <arm_group>
    <arm_group_label>Lenzilumab Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV infusion of lenzilumab upon randomization at a pre-specified dosing interval and continued administration of standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive IV infusion of preservative-free 0.9% sodium chloride solution upon randomization matched to lenzilumab at same pre-specified dosing interval and continued administration of standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lenzilumab</intervention_name>
    <description>Administered as an intravenous (IV) infusion</description>
    <arm_group_label>Lenzilumab Arm</arm_group_label>
    <other_name>Humaneered® anti-human GM-CSF monoclonal Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies</description>
    <arm_group_label>Lenzilumab Arm</arm_group_label>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults 18 years of age or older who are capable of providing informed consent or have&#xD;
             a proxy capable of giving consent for them&#xD;
&#xD;
          -  Virologic confirmation of SARS-CoV-2 infection via any FDA authorized diagnostic test&#xD;
             for SARS-CoV-2&#xD;
&#xD;
          -  Pneumonia diagnosed by Chest X-ray or Computed Tomography revealing infiltrates&#xD;
             consistent with pneumonia&#xD;
&#xD;
          -  SpO2 ≤ 94% on room air and/or require low-flow supplemental oxygen and/or require&#xD;
             high-flow oxygen support or NIPPV&#xD;
&#xD;
          -  Hospitalized, not requiring invasive mechanical ventilation during this&#xD;
             hospitalization&#xD;
&#xD;
          -  Have not participated in other clinical trial for COVID-19 using an immunomodulatory&#xD;
             monoclonal antibody or kinase inhibitor (use of remdesivir, corticosteroids,&#xD;
             convalescent plasma, hydroxychloroquine or chloroquine is permitted)&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requiring invasive mechanical ventilation or extracorporeal membrane oxygenation prior&#xD;
             to randomization&#xD;
&#xD;
          -  Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or&#xD;
             viral infections at screening/baseline&#xD;
&#xD;
          -  Known active tuberculosis (TB), history of incompletely treated TB or suspected or&#xD;
             known extrapulmonary TB&#xD;
&#xD;
          -  Currently receiving treatment for hepatitis A, hepatitis B, hepatitis C or HIV&#xD;
             infection&#xD;
&#xD;
          -  History of pulmonary alveolar proteinosis (PAP)&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant or breastfeeding&#xD;
&#xD;
          -  Known hypersensitivity to lenzilumab or any of its components&#xD;
&#xD;
          -  Use of any FDA authorized anti-IL-6 (e.g., tocilizumab, sarilumab, sitlukimab),&#xD;
             anti-IL-1 (e.g., anakinra, canakinumab), kinase inhibitor (e.g., baracitinib,&#xD;
             ibrutinib, acalabrutinib), or neutralizing monoclonal antibody (e.g. bamlanivimab or&#xD;
             casirivimab/imdevimab) therapy to treat COVID-19 within 8 weeks prior to randomization&#xD;
&#xD;
          -  Use of GM-CSF agents (e.g., sargramostim) within prior 2 months of randomization&#xD;
&#xD;
          -  Expected survival &lt; 48h in the opinion of the investigator&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, is likely to interfere with&#xD;
             the safety and efficacy of the study treatment or puts the patient at unacceptably&#xD;
             high risk from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cameron Durrant, MD</last_name>
    <role>Study Director</role>
    <affiliation>Humanigen, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Omar Ahmed, PharmD</last_name>
    <phone>201-509-0713</phone>
    <email>oahmed@humanigen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CTI Clinical Trial &amp; Consulting Services (CRO)</last_name>
    <phone>513-598-9290</phone>
    <email>HumanigenPhase3@ctifacts.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Southern California (USC) Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC - Los Angeles County Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Healthcare</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. David's Healthcare</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. David's North Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Health</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vera Cruz</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30140-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CPCLIN - Centro de Pesquisas Clínicas de Natal</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas - PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sociedade Literaria e Caritativa Santo Agostinho</name>
      <address>
        <city>Criciúma</city>
        <state>Santa Catarina</state>
        <zip>88811-500</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Dia do Pulmão</name>
      <address>
        <city>Blumenau</city>
        <state>São Paulo</state>
        <zip>89030-101</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Guilherme Alvaro</name>
      <address>
        <city>Santos</city>
        <state>São Paulo</state>
        <zip>11045-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica de Alergia Martti Antila S/S LTDA</name>
      <address>
        <city>Sorocaba</city>
        <state>São Paulo</state>
        <zip>18040-425</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CEMEC - Centro Multidisciplinar de Estudos Clínicos LTDA-EPP</name>
      <address>
        <city>São Bernardo do Campo</city>
        <state>São Paulo</state>
        <zip>09715-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Escola Paulista de Medicina (UNIFESP)</name>
      <address>
        <city>São Paulo</city>
        <zip>04037-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Heliópolis</name>
      <address>
        <city>São Paulo</city>
        <zip>04231-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital São Luiz do Jabaquara/IDOR</name>
      <address>
        <city>São Paulo</city>
        <zip>04501-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)</keyword>
  <keyword>GM-CSF monoclonal antibody</keyword>
  <keyword>Cytokine Release Syndrome (CRS)</keyword>
  <keyword>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</keyword>
  <keyword>Lenzilumab</keyword>
  <keyword>Cytokine Storm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

